Search results for "Cancer Pain"

showing 10 items of 134 documents

Does pain intensity predict a poor opioid response in cancer patients?

2011

Abstract Aim The aim of this study was to test the hypothesis that initial pain intensity is not a predictive factor of poor opioid response in advanced cancer patients, as suggested by a recent work. Methods A secondary analysis of one-hundred-sixty-seven patients referred for treatment of cancer-related pain was conducted. Pain intensity at admission was recorded and patients were divided in three categories of pain intensity: mild, moderate and severe. Patients were offered a treatment with opioid dose titration, according to department policy. Data regarding opioid doses and pain intensity were collected after dose titration was completed. Four levels of opioid response were considered:…

MaleCancer ResearchOpioid responseopioid response in cancer patientPainOpioidSettore MED/42 - Igiene Generale E ApplicataSecondary analysisNeoplasmsmedicineHumansProspective StudiesCancer painKarnofsky Performance StatusAdverse effectAgedPain Measurementpain intensityAnalgesicsAnalysis of VarianceAssessment tools; Cancer pain; Opioid response; Aged; Analgesics Opioid; Analysis of Variance; Female; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasms; Pain; Pain Measurement; Prospective Studies; Treatment Outcome; Cancer Research; Oncologybusiness.industryCancerMiddle Agedmedicine.diseaseAdvanced cancerIntensity (physics)Predictive factorAnalgesics OpioidAssessment toolsTreatment OutcomeOncologyOpioidAnesthesiapain intensity; opioid response in cancer patients; trial clinicoFemaletrial clinicoCancer painbusinessmedicine.drugEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.

2010

The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain.This was a nonrandomized, open-label, uncontrolled study in fifty consecutive opioid-naive patients with advanced cancer and moderate pain. TD fentanyl was initiated at a dose of 12 µg/h. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD fentanyl doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated.Thirty-one patients completed all 4 weeks of the study. Pain control was achieved within a me…

MaleTransdermal patchCancer pain; Opioids; Trandermal fentanyl; Aged; Analgesia; Analgesics Opioid; Dose-Response Relationship Drug; Female; Fentanyl; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms; Pain; Palliative Care; Transdermal Patch; Medicine (all)medicine.medical_treatmentPainTransdermal PatchOpioidFentanylDose-Response RelationshipNeoplasmsmedicineHumansCancer painAdverse effectNeoadjuvant therapyTransdermalAgedAnalgesicsDose-Response Relationship Drugbusiness.industryMedicine (all)Palliative CareGeneral MedicineMiddle AgedNeoadjuvant TherapyOpioidsClinical trialAnalgesics OpioidFentanylTolerabilityTrandermal fentanylAnesthesiaFemaleDrugAnalgesiaCancer painbusinessmedicine.drugCurrent medical research and opinion
researchProduct

Effects of age and gender in patients receiving doses of opioids for breakthrough pain proportional to background opioid doses.

2019

Aim: To identify the role of age and gender in analgesic and adverse effects after administering fentanyl products for breakthrough pain (BT), given in doses proportional to opioid doses given for background pain. Methods: Data from nine studies, in which patients with BP were given fentanyl products in doses proportional to their basal opioid regimen, were analyzed. Results: A total 462 patients presenting 1905 episodes of BP were included in this analysis. In older patients, the decrease in pain intensity was more pronounced 15 min after administration of a BP medication. No gender differences were found. No significant differences in frequency and intensity of adverse effects for age and…

MalePain medicineAnalgesicFentanyl03 medical and health sciencesBasal (phylogenetics)Age0302 clinical medicinemedicineHumans030212 general & internal medicineCancer painAdverse effectAgedPain Measurementbusiness.industryBreakthrough PainAge FactorsGenderGender IdentityFentanylAnalgesics OpioidRegimenTreatment OutcomeOncologyOpioid030220 oncology & carcinogenesisAnesthesiaFemaleCancer painbusinessmedicine.drugSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
researchProduct

Pharmacological Management of Cancer Pain in the Elderly

2007

Existing studies indicate a high prevalence rate and poor management of cancer pain in the elderly. Pain is often considered an expected concomitant of aging, and older patients are considered more sensitive to opioids. Despite the well known pharmacokinetic changes in the elderly, the complex network of factors involved in the opioid response make the evaluation of a single element, such as age, more difficult. Notwithstanding such difficulties, appropriate analgesic treatment is able to control cancer pain in the elderly in most cases. Skills necessary to optimise pain control in older cancer patients include the ability to objectively assess functional age (not necessarily related to chr…

medicine.medical_specialtybusiness.industryAnalgesicChronic painPainCancerAnalgesics Non-Narcoticmedicine.diseaseAnalgesics OpioidPharmacotherapyQuality of lifeOpioidChemotherapy AdjuvantNeoplasmsmedicinePhysical therapyHumansPharmacology (medical)Geriatrics and GerontologyIntensive care medicineAdverse effectbusinessCancer painAgedmedicine.drugDrugs & Aging
researchProduct

Effects of Caffeine as an Adjuvant to Morphine in Advanced Cancer Patients

2001

Psychomotor abnormalities are one of the complications of opioid therapy in advanced cancer patients. Caffeine has potential properties to counteract the central effects of morphine. Twelve patients receiving stable doses of slow release morphine with adequate pain relief were scheduled for this double-blind placebo-controlled crossover trial. The treatment consisted of an intravenous dose of 1/6 of the daily morphine dose, using an intravenous/oral conversion ratio of 1:3. The dose calculated was administered in 5 minutes. Patients were randomly divided to received in a double-blind manner an infusion of 200 mg of caffeine or saline solution intravenously over one hour. A crossover took pl…

business.industryPlacebo-controlled studyPlaceboCrossover studychemistry.chemical_compoundAnesthesiology and Pain MedicineBolus (medicine)chemistryOpioidAnesthesiamedicineMorphineNeurology (clinical)CaffeineCancer painbusinessGeneral Nursingmedicine.drugJournal of Pain and Symptom Management
researchProduct

Opioid-induced hyperalgesia after rapid titration with intravenous morphine: Switching and re-titration to intravenous methadone.

2012

Rapid titration with intravenous morphine (IV-MO) provides fast and efficient pain relief in cancer patients with severe-excruciating pain. However, some patients, after an initially favourable response, can develop an hyperexcitated state unrelieved or worsened by further dose increments.Eighty-one patients admitted on emergency basis titrated with IV-MO were assessed.12 patients were unsuccessfully titrated with IV-MO. Switching to intravenous methadone (IV-ME) and titrating the doses proved to be successfully.In escalating opioid doses rapidly a recognition of the development of hyperalgesia should be suspected. Increasing doses of opioids may stimulate rather than inhibiting the central…

opioid switchingCancer painopioid-induced hyperalgesiaSettore MED/42 - Igiene Generale E Applicataopioid titrationAnnals of palliative medicine
researchProduct

Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A …

2016

Context Fentanyl products have shown superiority over oral opioids for the management of breakthrough cancer pain (BTcP). However, these studies did not use an appropriate patient selection, and drugs have been compared using a different rationale. Objectives The aim of this randomized, crossover, controlled study was to compare the efficacy and safety of fentanyl pectin nasal spray (FPNS) and oral morphine (OM), given in doses proportional to opioid daily doses. Methods Cancer patients with pain receiving ≥60 mg of OM equivalents/day and presenting with ≤3 episodes of BTcP/day were included. Patients received, in a randomized, crossover manner, FPNS or OM at doses proportional to the d…

Malefentanyl pectin nasal spraymedicine.medical_treatmentAdministration OralContext (language use)Fentanyl03 medical and health sciences0302 clinical medicinemedicineHumansCancer painGeneral NursingNursing (all)2901 Nursing (miscellaneous)Pain MeasurementAnalgesicsCross-Over StudiesMorphinebusiness.industryNasal SpraysMiddle Agedbreakthrough painCrossover studyFentanylRegimenTreatment OutcomeAnesthesiology and Pain MedicineOpioidNasal sprayoral morphine030220 oncology & carcinogenesisAnesthesiaMorphinePectinsFemaleNeurology (clinical)businessCancer painbreakthrough pain; Cancer pain; fentanyl pectin nasal spray; oral morphine; Nursing (all)2901 Nursing (miscellaneous); Neurology (clinical); Anesthesiology and Pain Medicine030217 neurology & neurosurgerymedicine.drug
researchProduct

An Italian survey on the attitudes in treating breakthrough cancer pain in hospice.

2010

As recognition and treatment of breakthrough cancer pain (BcP) depend on the education and knowledge of palliative care physicians, it is important to systematically explore the attitudes of palliative care physicians in hospices or palliative care units. The aim of this study was to assess the knowledge and attitudes of hospice physicians in Italy regarding BcP and its treatment. All hospices existing in Italy were interviewed to gather information about provision of BP medication, drugs of choice, preferred route of administration, methods to choose the dose, and choice of BcP medication based on opioid administered for background analgesia. Of 158 hospices registered, 122 centers agreed …

medicine.medical_specialtyHealth Knowledge Attitudes PracticePalliative carePain medicinePainSettore MED/42 - Igiene Generale E ApplicataFentanylRoute of administrationNeoplasmsmedicineHumanssurveyPractice Patterns Physicians'Intensive care medicineChi-Square Distributionbusiness.industryNursing researchAnalgesics OpioidRegimenbreakthrough cancer painHospice CareOncologyOpioidItalyhospiceHealth Care SurveysClinical CompetenceCancer painbusinessbreakthrough cancer pain; hospice; surveymedicine.drug
researchProduct

World Health Organization guidelines for cancer pain: a reappraisal

2005

Pain is a prevalent symptom experienced by at least 30% ofpatients undergoing an oncological treatment for metastaticdisease and by more than 70% of advanced cancer patients[1]. In 1986 the World Health Organization [2] published a setof guidelines for cancer pain management based on the three-step analgesic ladder [2]. The main aim of WHO guidelienswas to legitimize the prescribing of strong opioids, arisingfrom evidence of poor management of cancer pain, due toreluctance of health care professionals, institutions, and gov-ernment to use opioids because of fears of addition, toleranceand illegal abuse.Its application is reported to achieve satisfactory pain reliefin up to 90% of patients w…

medicine.medical_specialtyAlternative medicinePain reliefPainWorld Health OrganizationWorld healthAdrenal Cortex HormonesNeoplasmsHealth caremedicineHumansIntensive care medicineHigh rateAnalgesicsMorphinebusiness.industryBreakthrough PainSmall sampleHematologytransdermal fentanylAnalgesics OpioidOncologyOpioidAnesthesiaPractice Guidelines as TopicbusinessCancer painmedicine.drugAnnals of Oncology
researchProduct

Breakthrough pain in oncology: A longitudinal study

2010

Abstract Context Existing studies on breakthrough pain (BP) have reported different prevalence rates because of different settings, populations, and assessment methods. These studies have used cross-sectional designs, and the relationship of BP with analgesic treatment has not been evaluated. Objectives The aim of this study was to longitudinally assess BP in cancer patients admitted to oncology units. Methods A consecutive sample of patients admitted to oncology centers was selected. At admission (T0), three months after admission (T3), and six months after admission (T6), data on background pain and BP were recorded. BP was assessed in terms of its intensity, duration, number of episodes,…

Oncologybreakthrough pain; Cancer pain; epidemiology; oncology; Acute Disease; Aged; Analgesics; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasms; Pain; Severity of Illness Index; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous)Malemedicine.medical_specialtyLongitudinal studyBreakthrough PainAnalgesicPrevalencePainContext (language use)Severity of Illness Indexlongitudinal study; breakthrough pain; cancer patientsInternal medicineNeoplasmsEpidemiologymedicineHumansLongitudinal StudiesStage (cooking)Cancer painGeneral NursingNursing (all)2901 Nursing (miscellaneous)AgedAnalgesicsbusiness.industrylongitudinal studyMiddle Agedbreakthrough painTreatment OutcomeAnesthesiology and Pain MedicineoncologyAcute DiseaseepidemiologyFemaleNeurology (clinical)cancer patientsbusinessCancer pain
researchProduct